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Abstract
Objective: The study was conducted to evaluate the effi-
cacy and safety of levetiracetam in migraine prophylaxis
in young patients.
Methods: Ten consecutive patients aged 12–21 years with
typical or atypical migraine were reviewed prior to and fol-
lowing the administration of levetiracetam for 6 months
(750–2250 mg/day).
Results: Headache score, duration, and frequency showed
considerable improvement in all patients compared to base-
line. Headaches were eliminated in 3 patients. Electroen-
cephalogram showed dysrhythmia grade 2 or 3 at
baseline, which improved to grade 1 in all patients following
the treatment period.
Conclusion: In this pilot study, levetiracetam was effective
and well tolerated. The improvements in headache out-
comes in this group of patients may be due, in part, to
the effect of levetiracetam on electroencephalogram dys-
rhythmias. These preliminary results of levetiracetam seem
to be promising in relieving headaches in the pediatric age
group.
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Migraine headache is common among the pediatric and ado-
lescent population, with prevalence rates ranging from approx-
imately 3% to 4% in early ages1,2 to as high as 8% to 23%
during adolescence.3,4 Before puberty, boys have more head-
aches than girls, but after puberty, migraine headaches occur
more frequently in girls.5
Standard management is an important consideration in
younger patients with migraine, particularly during critical
periods of academic and social development.6 Therapy is
often individualized and can include both pharmacological
and non-pharmacological measures.7 Preventative treatment
strategies are often employed as a means to reduce the fre-
quency, severity, and duration of attacks. Pharmacologic
agents currently used in migraine prophylaxis include beta-
blockers, antidepressants, calcium channel antagonists, and
anticonvulsants.
Although anticonvulsants have been studied and are
currently used in pediatric migraine prophylaxis, none are cur-
rently approved for this use in pediatric patients. Levetirace-
tam, an anticonvulsant with a unique mechanism of action,
has been associated with good efficacy and tolerability in adult
and pediatric migraine management.6,8–10 Recent studies have
highlighted the potential use of levetiracetam in pediatric
migraine prophylaxis.6,10 In both studies, significant decreases
in mean headache frequency were observed at dosages similar
to those used in epilepsy patients, with good tolerability.
Although no prospective, well-controlled data are available
evaluating the use of levetiracetam in pediatric migraine, its
pharmacologic characteristics – including minimal protein
binding, lack of cytochrome P450 metabolism, and no drug–
drug interactions – in addition to its established safety profile
in young patients,11 which makes it an attractive candidate for
evaluation in pediatric migraine. The objective of this study
was to evaluate the efficacy and safety of levetiracetam in
migraine prophylaxis in young patients.
Materials and Methods
The present study was a retrospective analysis of 10 consecu-
tive patients with typical or atypical migraine treated with
levetiracetam at a single center. Eligible patients included
patients aged 12–21 years diagnosed with migraine with or
without aura according to International Headache Society
(IHS) criteria and non-responsiveness (or failure) to traditional
headache management. The rationale for using levetiracetam
was based on treatment failure with prior headache medica-
tions. An average of 2 to 3 prior treatments for migraine had
been utilized, including sodium valproate, topiramate,
propranolol or oxcarbazepine. Before starting levetiracetam,
all other medications were discontinued, followed by a wash
out period of 1 week and then levetiracetam as monotherapy
was started.
All patients underwent a 6-month treatment with
levetiracetam. Clinical characteristics were reviewed prior to
treatment (baseline) and after 6 months (post-treatment) for
efficacy and safety measures. Patient records were reviewed
for the following characteristics: age, gender, any prior or
current migraine medication usage; levetiracetam dosage
and titration history; scores on standardized headache
intensity scales; headache duration; headache frequency;
standard one-hour electroencephalogram (EEG) findings
(non-ambulatory); and adverse events. The headache score
was based on a scale of 1 (mild) to 10 (severe). Headache
duration was scored in minutes, and frequency was scored
as headaches per week or month. Scoring of EEG was
performed using a standard grading system of dysrhythmia
1 to 3.
Results
Baseline characteristics
Ten consecutive patients were identified who met IHS criteria
for typical or atypical migraine and were treated with leveti-
racetam, and comprised the study population. There were six
males with a mean age of 15.5 years (Table 1). Associated signs
and symptoms were common among the study population,
and included dizziness, aggression, or tics. At the time of pre-
sentation, headache duration ranged from 15 min to 24 h,
while headache frequency typically ranged from 2 to 4 per
week (two patients suffered from daily headaches). Baseline
headache score ranged from 5 to 9.
Headache outcome
The mean dosage of levetiracetam was 1525 mg/day (range
750–2250 mg/day). As all patients’ weight ranged between
50% and 75% percentile for their age and sex, the average
dosage of levetiracetam ranged between 20 and 60 mg/kg/day
divided twice a day.
Following 6 months of treatment, all patients were classi-
fied as responders. Mean headache duration was reduced to
seconds in 3 patients; duration ranged from 1 to 5 min in all
but one of the remaining patients (Table 1). In 3 (30%)
patients, levetiracetam was associated with elimination of
headaches. Headache frequency in the remaining patients ran-
ged from 1 to 4 per month, representing a considerable
improvement from the baseline.
Headache score dropped to 1 or 2 in seven patients (Table 1),
a decrease of approximately 6 to 7 points from baseline in the
majority of patients. A score of 3 was the highest score
observed following treatment with levetiracetam.
EEG findings
At baseline, abnormal findings on EEG (dysrhythmia grade 2
or 3) were found in all patients. Post-treatment EEG revealed
grade 1 dysrhythmia in all patients.
Safety
Five patients could be weaned from levetiracetam during the
course of the study due to overall improvement in migraine
symptoms. A recurrence of migraine, however, was subse-
quently observed in all patients, which required the reintroduc-
tion of levetiracetam. This again led to the cessation of
migraine. Levetiracetam was well tolerated in this group of pa-
tients. Three adverse events were noted; agitation, acne, and
weight gain, occurring in one patient each.
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76 Treatement of pediatric headache with LevetiracetamDiscussion
The scarcity of approved and authentic medications for pedi-
atric migraine prophylaxis, in light of its high prevalence,
makes the findings of this study suitable alternative treatment.
In this study of pediatric patients with typical or atypical mi-
graine, levetiracetam was associated with decreases in head-
ache score, duration, and frequency, with subsequent
improvement in EEG.
There are limited data on the use of levetiracetam in pedi-
atric migraine. Our results agree with previous studies,6 who
found elimination of migraine in 10 of 19 children (mean age
12 years) in a retrospective review. Migraine was classified as
severe in most patients. The mean duration of treatment was
4.1 months at a levetiracetam dosage ranging from 125 to
750 mg twice daily. Headache frequency decreased from 6.3
to 1.7 (p< 0.0001) monthly following treatment. Only 3 pa-
tients complained of side effects, which included asthenia/som-
nolence or behavioral issues. A recent open-label study of 20
children with migraine (mean age 10.7 years) revealed a posi-
tive response to levetiracetam in 18 of 20 patients (P50%
reduction in monthly headache frequency).10 Mean headache
frequency decreased from 6.0 to 2.0 per month following treat-
ment with levetiracetam (p< 0.001); 8 patients achieved this
response at a dosage of 20 mg/kg/day. Tolerability was similar
to the current study as well as that reported previously,6 as
only 3 patients reported adverse events; behavioral changes
in 2 patients and mild memory problems in one. Striking fea-
ture of this study was the fact that all 10 children had abnor-
mal EEG findings at baseline. The decision to perform the
EEG was made based on the lack of traditional ‘classic’ mi-
graine symptoms on physical examination. By taking a slightly
more detailed history, symptoms began to emerge that sug-
gested possible simple partial epilepsy. Some authors do not
recommend the use of EEG as a diagnostic tool in pediatric
headache evaluation,12 although in certain instances it may
be useful. In our cases, the initial suspicions of epilepsy were
confirmed by performing EEG.
Association between migraine and few epilepsy syndromes
has been previously reported, though data were conflicting
and most studies have been limited by the small sample sizes.13
Furthermore, examination of 1795 patients under the age of 18
with headache showed that 3.1% had both headache and epi-
lepsy; with migraine to be associated 3.2 times more frequently
than Tension Type Headache (TTH); conversely, children with
epilepsy had a 4.5 increased risk of having migraine compared
with TTH.13 The current understanding of migraine patho-
physiology demonstrates a migrating wave of regional cortical
excitation followed by a prolonged period of neuronal depres-
sion, which may be altered by antiepileptics. Numerous retro-
spective studies show a reduction in headache severity with
antiepileptic drugs.14 Further studies, based on the updated
diagnostic criteria of both disorders are needed.15
Clearly, more prospective studies are needed in children to
assess efficacy and tolerability for use in migraine prevention.
Beta-blockers, while often viewed as one of the first-line agents
in children, have failed to consistently demonstrate effective-
ness in randomized, double-blind studies.2
A 100% response in 7 of 8 patients (mean age 13 years)
with complex partial seizures and migraine, at a levetiracetam
dosage range of 24–72 mg/kg was reported; EEG was not
performed.16 A recent report found that 14 of 137 children
with tension-type headache and idiopathic migraine with and
without aura had a positive history for seizures with fever, iso-
lated seizures, or epilepsy.17 Abnormalities in EEG were pres-
ent in 11.7% of the patients. Specific interictal EEG
abnormalities and seizures showed a different distribution in
patients with migraine with aura compared to other headache
classes and controls; the authors concluded that the results
showed a clearly altered neuronal excitability in these patients.
Although the basis for resolution of migraine with levetirace-
tam treatment is not completely understood, it may be in part
due to its effects on EEG.
Limitations of this study include the retrospective nature of
the study design, and the lack of an appropriate control group.
Our population consisted of 10 consecutive patients (no special
selection), however, and all 10 showed improvements in head-
ache outcomes and on EEG. The adverse events seen in this
study are consistent with those observed in other trials of lev-
etiracetam and pediatric migraine6,10 and are also consistent
with the known safety profile of the drug in pediatric
patients.11
In summary, the use of levetiracetam was associated with
decreases in headache score, duration, and frequency in young
patients with migraine. The drug was well tolerated. Subse-
quent improvement in EEG dysrhythmias was also seen, and
represents an area of potential explanation for the efficacy of
levetiracetam in migraine. These preliminary results of leveti-
racetam seem to be promising in relieving headaches in the
pediatric age group. Further prospective, well-controlled clin-
ical studies are required to substantiate these findings.
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